Amiodarone: Uses, Thyroid Effects and Other Safety Findings

Amiodarone is one of the most widely used drugs for an irregular heartbeat, and also one of the drugs with the longest list of recorded side effects. It is rich in iodine and stays in the body for weeks to months, and both facts shape what the research records about it: changes in the thyroid gland, the lungs, the liver, the eyes, the skin and the nerves, and interactions with other common heart medicines. This page reports what guidelines, large population studies and reviews have found, with the numbers exactly as those records give them.

Table of Contents

  1. A Class III Heart-Rhythm Drug
  2. A Large Iodine Load and a Slow Exit
  3. What Placebo-Controlled Trials Measured
  4. Thyroid Blood Tests Shift
  5. Amiodarone-Induced Hypothyroidism
  6. Two Types of Amiodarone-Induced Thyrotoxicosis
  7. How Often Thyroid Problems Occur
  8. Lung Toxicity
  9. Liver Findings
  10. Eye Findings
  11. Skin Findings
  12. Nerve Findings
  13. Warfarin, Digoxin and Statin Interactions
  14. Monitoring Described by Guidelines
  15. What Remains Unknown
  16. Key Research Papers
  17. Connections
  18. Featured Videos

Amiodarone Is a Class III Heart-Rhythm Drug

Amiodarone is an antiarrhythmic drug: a medicine used to control abnormal heart rhythms. A 1991 pharmacology review describes it as a unique agent that was originally developed as a vasodilator (a drug that widens blood vessels) and is classified electrophysiologically as a Type III antiarrhythmic, while also having nonspecific antisympathetic effects and direct effects on the heart's fast channels. A 2020 clinical review adds that, although it is classified as class III, it affects all phases of the cardiac action potential (the electrical cycle of each heartbeat), and a 2024 review states that it shows antiarrhythmic properties across all four classes of antiarrhythmic drugs.

Its official approval is narrower than its use. A 2007 evidence review in JAMA states that amiodarone is approved by the US Food and Drug Administration only for refractory ventricular arrhythmias (dangerous rhythms arising in the lower chambers of the heart that have not responded to other treatment), yet it is one of the most frequently prescribed antiarrhythmic medications in the United States. That review found evidence for these settings:

The 2024 review states that amiodarone is highly effective in maintaining a normal (sinus) rhythm in people with paroxysmal atrial fibrillation and plays a crucial role in preventing a range of ventricular arrhythmias. The conditions themselves are covered on the Atrial Fibrillation and Ventricular Tachycardia pages.

Back to Table of Contents

Each Dose Carries a Large Iodine Load and Leaves the Body Slowly

Iodine content. A 2021 review in the Journal of Clinical Endocrinology and Metabolism describes amiodarone as a class III antiarrhythmic drug containing 37% iodine by weight, with a structure similar to that of thyroid hormones. The review states that the breakdown (deiodination) of amiodarone releases large amounts of iodine that can impair thyroid function. Why a large iodine load can inflame or disturb the thyroid is explained on the companion page Iodine Excess: Thyroiditis.

Absorption. The drug is absorbed unevenly from the gut. The 1991 review gives an oral bioavailability of 20–80%; a 1984 pharmacokinetics review describes absorption as erratic and unpredictable, with oral bioavailability ranging from 22 to 86%. In vitro, 96.3% of amiodarone is bound to blood proteins, according to the 1984 review.

Storage in fat. Amiodarone is highly lipophilic (fat-loving). The 1984 review states that adipose tissue and skeletal muscle accumulate large amounts of the drug during long-term treatment. The 1991 review describes exceptionally high tissue-to-plasma partition coefficients and notes that its main breakdown product, mono-N-desethylamiodarone, is itself an antiarrhythmic.

A very long half-life. The time the body takes to clear half of the drug depends on how long it has been taken:

The 1984 review also records that less than 1% of a dose leaves unchanged in the urine, that placental transfer of amiodarone has been demonstrated in humans, and that its blood profile is not changed by dialysis.

Back to Table of Contents

Placebo-Controlled Trials Measure the Overall Side-Effect Burden

Two meta-analyses pooled randomised trials that compared amiodarone with a dummy pill (placebo). They give the clearest picture of which side effects are truly caused by the drug, because the placebo group shows how often the same problems occur anyway.

The 1997 low-dose meta-analysis. Pooling 4 double-blind trials with 1,465 patients (738 given amiodarone, 727 placebo) and a mean daily dose of 152 to 330 mg for at least 12 months, the authors found odds similar to placebo for liver and gastrointestinal side effects, but significantly higher odds for:

There was a trend toward more lung toxicity that did not reach statistical significance (p = 0.07). The unadjusted rate of stopping the drug was 22.9% with amiodarone and 15.4% with placebo. The authors concluded that low-dose amiodarone may be well tolerated but is not free of adverse effects.

The 2019 meta-analysis. A larger pooling of 43 randomised trials with 11,395 patients (5,792 given amiodarone, 5,603 placebo) reported side-effect rates per 10,000 person-years:

Low-dose amiodarone was not associated with a statistically significant increase in lung side effects in that analysis, but was still associated with thyroid and liver side effects. The authors wrote that the overall rate of adverse events was low and severe adverse events were rare.

A long-term follow-up in everyday practice. A French prospective study followed 98 people newly started on amiodarone (mean age 72.6 years) for a mean of 38 months. Side effects occurred at a rate of 13.91 per 100 person-years. Recorded were 13 cases of hypothyroidism, 5 of hyperthyroidism, 10 of slow heart rate or conduction problems, 7 of photosensitivity, 3 of interstitial pneumonitis, 2 of peripheral neuropathy, 1 storage disease, 1 tremor and 1 of gastrointestinal upset. Thyroid and heart side effects occurred mainly during the first 6 months, and none was fatal in that study.

Back to Table of Contents

Thyroid Blood Tests Shift Even in a Healthy Gland

A 2001 review in Endocrine Reviews by Martino, Bartalena, Bogazzi and Braverman states that amiodarone often causes changes in thyroid function tests, typically a rise in serum thyroxine (T4) and reverse T3 and a fall in serum triiodothyronine (T3). The review relates these changes mainly to the drug's blocking of 5′-deiodinase, the enzyme that turns T4 into the active hormone T3. A 1989 review in Clinical Chemistry describes the same pattern.

The 2018 European Thyroid Association guideline separates these laboratory changes from true thyroid disease: it states that treatment with amiodarone is associated with changes in thyroid function tests, but also with thyroid dysfunction — amiodarone-induced hypothyroidism and amiodarone-induced thyrotoxicosis. The 2021 review adds that not only the excess iodine but also amiodarone itself, or its breakdown product desethylamiodarone, may cause thyroid dysfunction by direct toxicity to thyroid cells. How these tests are read is covered on the Thyroid Panel page.

Back to Table of Contents

Amiodarone-Induced Hypothyroidism Is the Underactive Form

In amiodarone-induced hypothyroidism, the gland makes too little hormone. The 2018 European Thyroid Association guideline states that both this condition and the overactive form may develop in apparently normal thyroid glands or in glands with underlying thyroid abnormalities.

The general condition is described on the Hypothyroidism page.

Back to Table of Contents

The 2018 European Guideline Describes Two Types of Overactive Thyroid

Amiodarone-induced thyrotoxicosis means too much thyroid hormone in the blood caused by the drug. The 2018 European Thyroid Association guideline recognises two main types:

The guideline describes different treatments for each type:

The 2001 Endocrine Reviews paper adds that radioiodine therapy is usually not feasible because the gland's radioiodine uptake is low, and that thyroidectomy can be performed in cases resistant to medical therapy, with a slightly increased surgical risk. The broader conditions are covered on the Hyperthyroidism page and, for the iodine side, the Iodine Excess: Thyroid Dysfunction page.

Back to Table of Contents

Thyroid Problems Are Common in Long-Term Users

Estimates vary with the population, its iodine intake, and how long people were followed:

The Korean authors note that hypothyroidism was more common than thyrotoxicosis in an area with sufficient iodine intake.

Back to Table of Contents

Lung Toxicity Is the Most Feared Finding

Several records name lung injury as amiodarone's most serious side effect: a 2007 Japanese study calls amiodarone-induced pulmonary toxicity the most serious side effect, a 2024 Israeli study calls amiodarone-related interstitial lung disease (scarring and inflammation of lung tissue) the most severe adverse effect, and a 1999 review states that, in terms of its toxicity, amiodarone remains the most feared of the antiarrhythmic agents.

How often it occurs. The estimates disagree widely, which is itself a finding:

What it looks like. The 2010 review states that lung effects may develop from the first few days of treatment to several years later, with an onset that may be insidious or rapidly progressive. It lists cough, new shadows on chest imaging and reduced lung diffusing capacity as the cardinal elements of diagnosis, after infection, cancer and fluid on the lungs have been carefully excluded. The 1999 review describes an indolent onset of cough, malaise and fever with patchy shadows at the edges of the lungs and severely decreased diffusion capacity.

Who the research raises concerns for. The 2010 review links lung complications to older age, duration of treatment and cumulative dose, high levels of the desethyl metabolite, previous heart or chest surgery or use of high oxygen mixtures, use of iodinated contrast media, and probably pre-existing lung disease and coexisting respiratory infections. The 1999 review states that people with pre-existing lung disease appear to be more at risk.

Outcome. The 2010 review reports mortality ranging from 9% for those who develop chronic pneumonia to 50% for those who develop acute respiratory distress syndrome. It describes stopping the drug, controlling risk factors and, in more severe cases, corticosteroids as possibly of therapeutic value. The 1999 review states that most cases recover once amiodarone is stopped, and that steroids are commonly used but of unproved efficacy.

Back to Table of Contents

Liver Enzyme Rises Are Common, Liver Failure Is Rare

A 2008 review of amiodarone hepatotoxicity states that liver injury is mostly associated with long-term oral use, but has also been reported early during intravenous administration and months after the drug was stopped. In the majority of patients it is discovered incidentally during routine liver blood tests, and the review states that it rarely develops into symptomatic liver injury or failure.

The 2008 review notes that prospective clinical studies have been sparse and that there has been little consensus among experts on the best way to monitor for side effects.

Back to Table of Contents

Corneal Deposits Are Near-Universal, Optic Nerve Damage Is Uncommon

Corneal deposits. A 1999 review states that corneal microdeposits (tiny deposits in the clear front surface of the eye) are almost ubiquitous in people treated with amiodarone, but are for the most part benign and produce no change in visual acuity. The 2007 JAMA review lists them at over 90%. The 1999 review adds that the absence of microdeposits prompts physicians to check whether the drug is being absorbed or taken as prescribed.

Optic neuropathy. Damage to the optic nerve is far rarer and far more serious:

The question of cause is not fully settled. The 1999 review states that no causal link between amiodarone and optic neuropathy had been proved, noting that people treated with amiodarone often have ischaemic disease or diabetes, which affect the retina and optic nerve. A 2022 review describes amiodarone-associated optic neuropathy as a complex diagnosis that has to be distinguished from non-arteritic ischaemic optic neuropathy, because the two share the same at-risk population. In the 1997 placebo-controlled analysis, eye side effects had an odds ratio of 3.4.

Back to Table of Contents

Sun Sensitivity and Blue-Grey Skin Are the Skin Findings

Back to Table of Contents

Nerve Findings Include Peripheral Neuropathy and Tremor

Back to Table of Contents

Warfarin, Digoxin and Statin Levels Rise With Amiodarone

A 1989 review of amiodarone's drug interactions states that its major mechanism is inhibition of drug breakdown in the liver, although it can also change the absorption, protein binding and kidney excretion of other drugs. It significantly increases blood levels of digoxin, warfarin, several class I antiarrhythmic drugs (quinidine, procainamide, aprindine and flecainide) and phenytoin, in some cases with clear signs of toxicity. The review states that in most cases 20 to 50% reductions in the doses of the affected drugs are necessary to offset these changes. With beta-blockers such as propranolol and calcium channel blockers such as diltiazem, the review describes additive effects on heart rhythm and blood pressure (slow heart rate and sinus arrest) rather than changes in drug levels.

Warfarin.

The clotting test itself is described on the PT/INR page.

Digoxin. The 1984 pharmacokinetics review records reports of rising steady-state digoxin levels, together with signs of digitalis toxicity, when amiodarone was given to people on long-term digoxin. A 1987 study in healthy volunteers who took 200 mg of amiodarone daily for 2 weeks found that amiodarone increased the peak level and total exposure of oral digoxin; absolute bioavailability rose by 36% and 43% in the two subjects who received both oral and intravenous digoxin, and the authors concluded that increased absorption of oral digoxin is the most relevant change.

Statins. A 2010 Veterans Affairs report states that the US Food and Drug Administration revised the labels of amiodarone and simvastatin in 2002 to warn of an increased risk of rhabdomyolysis (severe muscle breakdown, the most severe form of myopathy) when the two are taken together with simvastatin doses above 20 mg per day. The agency reissued the warning in 2008 after receiving 52 reports of rhabdomyolysis following the 2002 label changes, and suggested an alternative statin for people on amiodarone who require more than 20 mg of simvastatin. At that Veterans Affairs centre, 92 patients were on amiodarone together with simvastatin 40 mg or 80 mg daily, and most of them had additional risk factors for myopathy. A 2020 clinical review lists simvastatin and atorvastatin, warfarin and many HIV antiretroviral medications among the drugs amiodarone interacts with.

Back to Table of Contents

Monitoring Described by Guidelines and Reviews

This section reports what guidelines and study authors describe; decisions about any individual's medicines belong with their clinicians.

Back to Table of Contents

What Remains Unknown

Back to Table of Contents

Key Research Papers

  1. Bartalena L, Bogazzi F, Chiovato L, Hubalewska-Dydejczyk A, Links TP, Vanderpump M. 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. Eur Thyroid J. 2018;7(2):55-66. PubMed PMID: 29594056
  2. Sohn SY, Kim YJ, Cho S, Cho SW. Incidence and Risk Factors for Amiodarone-Induced Thyroid Dysfunction: A Nationwide Retrospective Cohort Study. Am J Cardiovasc Drugs. 2025;25(3):419-425. PubMed PMID: 39798058
  3. Guðjónsson P, Jóhannesson AJ, Eyþórsson E, Andersen K. Amiodarone induced thyroid dysfunction: A high cumulative incidence in a nationwide cohort study in Iceland. J Intern Med. 2025;298(3):228-236. PubMed PMID: 40637127
  4. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev. 2001;22(2):240-54. PubMed PMID: 11294826
  5. Ylli D, Wartofsky L, Burman KD. Evaluation and Treatment of Amiodarone-Induced Thyroid Disorders. J Clin Endocrinol Metab. 2021;106(1):226-236. PubMed PMID: 33159436
  6. Kennedy RL, Griffiths H, Gray TA. Amiodarone and the thyroid. Clin Chem. 1989;35(9):1882-7. PubMed PMID: 2673586
  7. Freedman MD, Somberg JC. Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol. 1991;31(11):1061-9. PubMed PMID: 1753010
  8. Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet. 1984;9(2):136-56. PubMed PMID: 6370540
  9. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007;298(11):1312-22. PubMed PMID: 17878423
  10. Hamilton D Sr, Nandkeolyar S, Lan H, Desai P, et al. Amiodarone: A Comprehensive Guide for Clinicians. Am J Cardiovasc Drugs. 2020;20(6):549-558. PubMed PMID: 32166725
  11. Șorodoc V, Indrei L, Dobroghii C, Asaftei A, et al. Amiodarone Therapy: Updated Practical Insights. J Clin Med. 2024;13(20):6094. PubMed PMID: 39458044
  12. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997;30(3):791-8. PubMed PMID: 9283542
  13. Ruzieh M, Moroi MK, Aboujamous NM, Ghahramani M, et al. Meta-Analysis Comparing the Relative Risk of Adverse Events for Amiodarone Versus Placebo. Am J Cardiol. 2019;124(12):1889-1893. PubMed PMID: 31653351
  14. Bongard V, Marc D, Philippe V, Jean-Louis M, et al. Incidence rate of adverse drug reactions during long-term follow-up of patients newly treated with amiodarone. Am J Ther. 2006;13(4):315-9. PubMed PMID: 16858166
  15. Rankin S, Elder DH, Ogston S, George J, et al. Population-level incidence and monitoring of adverse drug reactions with long-term amiodarone therapy. Cardiovasc Ther. 2017;35(3). PubMed PMID: 28276175
  16. Papiris SA, Triantafillidou C, Kolilekas L, Markoulaki D, et al. Amiodarone: review of pulmonary effects and toxicity. Drug Saf. 2010;33(7):539-58. PubMed PMID: 20553056
  17. Yamada Y, Shiga T, Matsuda N, Hagiwara N, et al. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J. 2007;71(10):1610-6. PubMed PMID: 17895560
  18. Tsaban G, Ostrovsky D, Alnsasra H, Burrack N, et al. Amiodarone and pulmonary toxicity in atrial fibrillation: a nationwide Israeli study. Eur Heart J. 2024;45(5):379-388. PubMed PMID: 37939798
  19. Pollak PT. Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations. Am J Cardiol. 1999;84(9A):37R-45R. PubMed PMID: 10568658
  20. Babatin M, Lee SS, Pollak PT. Amiodarone hepatotoxicity. Curr Vasc Pharmacol. 2008;6(3):228-36. PubMed PMID: 18673162
  21. Cheng HC, Yeh HJ, Huang N, Chou YJ, et al. Amiodarone-Associated Optic Neuropathy: A Nationwide Study. Ophthalmology. 2015;122(12):2553-9. PubMed PMID: 26391464
  22. Passman RS, Bennett CL, Purpura JM, Kapur R, et al. Amiodarone-associated optic neuropathy: a critical review. Am J Med. 2012;125(5):447-53. PubMed PMID: 22385784
  23. Mitchell R, Chacko J. Clinical and Mechanistic Review of Amiodarone-Associated Optic Neuropathy. Biomolecules. 2022;12(9):1298. PubMed PMID: 36139137
  24. Lesko LJ. Pharmacokinetic drug interactions with amiodarone. Clin Pharmacokinet. 1989;17(2):130-40. PubMed PMID: 2673606
  25. Heimark LD, Wienkers L, Kunze K, Gibaldi M, et al. The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther. 1992;51(4):398-407. PubMed PMID: 1563209
  26. Miano TA, Yang W, Shashaty MGS, Zuppa A, et al. The Magnitude of the Warfarin-Amiodarone Drug-Drug Interaction Varies With Renal Function: A Propensity-Matched Cohort Study. Clin Pharmacol Ther. 2020;107(6):1446-1456. PubMed PMID: 32112562
  27. Lu Y, Won KA, Nelson BJ, Qi D, et al. Characteristics of the amiodarone-warfarin interaction during long-term follow-up. Am J Health Syst Pharm. 2008;65(10):947-52. PubMed PMID: 18463344
  28. Santostasi G, Fantin M, Maragno I, Gaion RM, et al. Effects of amiodarone on oral and intravenous digoxin kinetics in healthy subjects. J Cardiovasc Pharmacol. 1987;9(4):385-90. PubMed PMID: 2438499
  29. Karimi S, Hough A, Beckey C, Parra D. Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center. J Manag Care Pharm. 2010;16(7):472-81. PubMed PMID: 20726676

PubMed Topic Searches

  1. PubMed: Amiodarone-induced thyrotoxicosis
  2. PubMed: Amiodarone-induced hypothyroidism
  3. PubMed: Amiodarone pulmonary toxicity incidence
  4. PubMed: Amiodarone hepatotoxicity
  5. PubMed: Amiodarone optic neuropathy
  6. PubMed: Amiodarone and warfarin interaction

Back to Table of Contents

Connections

Back to Table of Contents